D
SCYNEXIS, Inc. SCYX
$0.9043 -$0.0083-0.91% NASDAQ
Recommendation
Prev Close
$0.9043
Volume
88,193
Avg Vol (90D)
192,289
Market Cap
$35.25M
Dividend & Yield
--
52-Week Range
$0.7284 - $3.07
P/E (TTM)
--
EPS (TTM)
-$0.4426
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the ...
4/8/2025 - GuruFocus
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
4/8/2025 - The Fly
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
4/8/2025 - Globe Newswire
SCYNEXIS Reports 2024 Financial Results and Updates
3/14/2025 - TipRanks Financial Blog
SCYNEXIS GAAP EPS of -$0.44 misses by $0.98, revenue of $3.75M misses by $63.25M
3/13/2025 - SeekingAlpha.com: All News
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
3/12/2025 - Globe Newswire
Avidity Partners Management LP Acquires Additional Shares in SCYNEXIS Inc
2/14/2025 - GuruFocus
FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis
1/8/2025 - GuruFocus
Scynexis initiates dosing in Phase 1 trial of SCY-247
12/18/2024 - The Fly
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
12/18/2024 - Globe Newswire
SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86%
11/29/2024 - Simply Wall St
Avidity Partners Management LP's Strategic Acquisition in SCYNEXIS Inc
11/15/2024 - GuruFocus
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc
11/13/2024 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
11/11/2024 - TipRanks Financial Blog
SCYNEXIS's Strong Financial Position and Strategic Advancements Drive Buy Rating
11/8/2024 - TipRanks Financial Blog
Scynexis reports Q3 EPS (6c), consensus (7c)
11/6/2024 - The Fly
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving Average - Should You Sell?
10/22/2024 - MarketBeat - AP News
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average - Here's Why
10/12/2024 - MarketBeat - AP News
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
10/10/2024 - Globe Newswire
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc
10/7/2024 - GuruFocus
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below Two Hundred Day Moving Average - Here's What Happened
10/4/2024 - MarketBeat - AP News
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
10/3/2024 - Globe Newswire
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82
9/25/2024 - MarketBeat - AP News
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
8/27/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$3.75M
EBITDA (TTM)
-$36.54M
EBIT (TTM)
-$37.12M
Net Income (TTM)
-$21.29M
Balance Sheet
Total Assets (Q)
$90.64M
Total Debt (Q)
$16.27M
Total Liabilities (Q)
$35.57M
Book Value Per Share (Q)
$1.45
Cash Flow
Cash from Operations (TTM)
-$24.01M
Cash from Investing (TTM)
$6.15M
Cash from Financing (TTM)
-$139.00K
Net Change in Cash (TTM)
-$18.00M
Filings
Filing Date
Wednesday, March 12, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.53
7-Day Total Return
5.00%
30-Day Total Return
-6.55%
60-Day Total Return
-16.27%
90-Day Total Return
-24.64%
Year to Date Total Return
-37.63%
1-Year Total Return
-35.64%
2-Year Total Return
-72.09%
3-Year Total Return
-72.26%
5-Year Total Return
-91.13%
52-week Low
Apr 07, 2025 - $0.7284
52-week High
May 20, 2024 - $3.07
Valuation
Market Cap
$35.25M - Nano Cap
Enterprise Value
-$7.78M
Price/Sales (TTM)
11.76
Price/Book (Q)
0.62
Dividends and Shares
Shares Outstanding
48.67M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.scynexis.com
Phone Number
201 884 5485
Address
1 Evertrust Plaza
Jersey City, NJ 07302-6548
Country
United States
Year Founded
1999
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment... more
NASDAQ 04/17/2025 4:00PM Eastern Quotes delayed